Physician profile
Brian Forrest
NPI 1376540112
$397,532.07
in general payments reported to CMS, 2019-2025
19 companies · $104K in 2025
The $104K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $316 · 2021: $52K · 2022: $79K · 2023: $66K · 2024: $96K · 2025: $104K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $188K · Travel and Lodging: $43K · Consulting Fee: $24K · Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $188,475.00 |
| Travel and Lodging | $43,025.53 |
| Consulting Fee | $24,027.00 |
| Food and Beverage | $10,099.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $369,522.63 | 2019-2025 | Otezla, Otezla, Repatha |
| E.R. Squibb & Sons, L.L.C. | $18,035.26 | 2024-2025 | Camzyos, Eliquis |
| Pfizer INC. | $8,249.86 | 2022-2025 | |
| Regeneron Pharmaceuticals, INC. | $432.00 | 2025 | |
| Novo Nordisk INC | $386.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $327.59 | 2019-2023 | |
| Lilly USA, LLC | $167.10 | 2022-2025 | Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $76.39 | 2021-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $72.53 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $47.19 | 2019-2020 | |
| Horizon Therapeutics Plc | $44.03 | 2021-2022 | |
| Exact Sciences Corporation | $34.36 | 2024-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $33.72 | 2020 | |
| Daiichi Sankyo INC. | $23.38 | 2022 | |
| Abiomed | $19.38 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $18.04 | 2020 | |
| Medtronic USA, INC. | $15.07 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.57 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Forrest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.